We are glad to announce the launch of LolliSponge™, our latest collection and transport device!
Thanks to a close collaboration with the San Paolo Hospital in Milan, we have designed and released LolliSponge™ in only six months. A question might come to mind: what’s the point for the biggest producer of nasopharyngeal (NP) swabs to release a new saliva-collection product?
The answer is simple: although NP sampling remains the gold standard for SARS-CoV-2 detection, we are aware it is not always feasible, for example in non-collaborative patients like kids and old people. Moreover, although a high oral detection sensitivity has been demonstrated in the first phases of SARS-CoV-2 infection, most of the devices currently on the market are based on sputum collection, a procedure involving spitting-related infection risks and, as NP sampling, is not always possible to perform.
LolliSponge™ offers many advantages, from the easiness of collection to trouble-free transport and easy lab processing.
With this new device, we hope to enable Covid-19 active surveillance programs in fragile communities and drive professionals to other essential tasks such as vaccine administration. To make a long story short, we aim to help clinicians and laboratories worldwide in their daily activities.
Visit LolliSponge™ webpage and contact us for more information!